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Summary
Primary neoplasms of the heart are relatively rare. 
Their incidence varies between 0.001% to 0.3% of indi-
viduals in autopsy series. Even the most common pri-
mary tumour – cardiac myxoma – is estimated to occur 
in fewer than two or three people per 100 000 popula-
tion. When primary cardiac tumours occur conse-
quences may be considerable because of the crucial na-
ture of the various structures involved. The complica-
tions attributed to such tumours depend on their 
location, size, mobility, friability, and the invasiveness 
of tumour growth. Primary tumours of the heart and 
pericardium are more important for their local effects 
than for their potential metastatic behaviour. They 
usually present as rhythm disturbances, contractility 
abnormality, obstruction, valvular regurgitation, em-
bolic event, or pericardial effusion. In some instances, 
presentation may mimic myocardial ischaemia, valvu-
lar disease, cardiomyopathy, or local infectious disease. 
Numerous imaging modalities (transthoracic and 
transoesophageal echocardiography, computed tomog-
raphy and magnetic resonance imaging) have im-
proved the diagnosis and the planning for surgery 
when a heart tumour is suspected or discovered. Be-
nign cardiac tumours represent up to 75% of the cases. 
Surgical resection allows specification of the type of 
tumour in the majority of the cases. 
No randomised clinical trials have been carried out 
to determine the optimal therapy for primary cardiac 
tumours. The prognosis for survival in patients with 
cardiac tumours varies from excellent after resection 
of myxoma to dismal when malignant neoplasms 
have been diagnosed. Surgery may be the treatment of 
choice for small malignant tumours localised to the 
heart. Partial resection of large neoplasms to relieve 
mechanical effects might be considered in exceptional 
cases, especially in children. Whilst 
total resection of cardiac sarcomas 
may occasionally appear feasible, 
most operations are palliative and 
performed to relieve cardiac com-
pression or haemodynamic ob-
struction. 
This paper reviews the most common benign and 
malignant cardiac tumours, summarises some inter-
esting cases treated at our institution and gives an 
brief overview of our experience during the last 
15 years.
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Introduction
Cardiac tumours include benign and malign neoplasms 
within the cardiac chambers and the myocardium, as 
well as metastatic diseases. Tumours of the heart, 
while uncommon, may become symptomatic through 
obstruction, embolisation (sometimes characterised by 
distant growth of viable embolic material), and consti-
tutional manifestations (especially in cases of intracav-
itary tumours, for instance myxomas) [1–4]. Systemic 
tumour embolisation may occur as an initial manifes-
tation but care must also be taken that this complica-
tion does not occur intraoperatively. Therefore, partic-
ular attention has to be paid to avoid tumour fragmen-
tation during surgical exploration. The incidence of 
primary cardiac tumours in autopsies varies from 
0.001% to 0.3%, depending on the type of hospital, in 
which patients were hospitalised. There are numerous 
publications in the literature, showing that type and 
frequency of each tumour depends on whether the 
study was based on autopsy, surgical experience or 
reference centre material and whether they were per-
formed in a paediatric or an adult population. Primary 
cardiac tumours arise from the three layers of the 
heart (pericardium, myocardium, and endocardium) as 
well as from the connective tissue within the heart [1]. 
In some instances, rare diseases are sometimes consid-
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Imaging and diagnosis
Imaging plays a central role in the evaluation of car-
diac tumours, and familiarity with their characteristic 
features is essential in order to generate a meaningful 
differential diagnosis. In the past, 2-dimensional tran-
sthoracic echocardiography and transoesophageal 
echocardiography have proved to be extremely valua-
ble in the diagnosis of cardiac masses [8]. Nowadays, 
3-dimensional transthoracic and transoesophageal 
echocardiography offers the cardiologist and cardiovas-
cular surgeon the most accurate preoperative and 
intraoperative assessment of cardiac masses and 
correlates well with pathological findings [9]. However, 
sometimes anatomical and morphological information 
are incomplete. Real-time three-dimensional (3D) TEE 
is increasingly being used in general clinical practice. 
However, the use of real-time 3D TEE for the assess-
ment of atrial myxomas has not been described to date. 
Tolstrup and colleagues recently described a series of 
ten patients with left atrial myxomas undergoing two-
dimensional and real-time 3D TEE. They were able to 
demonstrate that 3D imaging accurately identifies 
these tumours and provides detailed morphological de-
scription of the tumours, which may have clinical im-
portance. In addition, because the 3D TEE is real time 
and can be performed preoperatively in the operating 
room, the surgeon may gain a complementary under-
standing of the nature and location of the tumour [9].
Beside echocardiography, cardiac magnetic reso-
nance imaging has become the imaging modality of 
choice for evaluation of suspected cardiac masses [10]. 
The majority of the patients will have undergone an in-
itial echocardiography. However, the latter exam suf-
fers from several limitations: restricted field of view, 
incomplete assessment of an invading cardiac mass 
due to an unfavourable patient body habitus, and lim-
ited ability to perform tissue characterisation. The role 
of magnetic resonance imaging in this setting is well 
established because of its ability to obtain a wide field 
of view, generate high contrast and spatial resolution, 
and perform multiplanar imaging, allowing precise 
demonstration and localisation of a mass [7]. 
Furthermore, magnetic resonance imaging helps 
discriminate between a true cardiac mass and a pseu-
domass. In addition, tissue characterisation by mag-
netic resonance imaging may serve in generating a dif-
ferential diagnosis, and can distinguish a cardiac neo-
plasm (which generally will require excision) from 
other conditions such as intracardiac thrombus, lipo-
matous hypertrophy or benign lipomas (all of which 
generally do not require excision). Finally, even when 
the aetiology of a mass remains known, magnetic reso-
nance may provide useful information regarding tu-
mour perfusion, invasiveness into cardiac or extracar-
diac structures and help to obtain tissue characterisa-
tion in selected cases [10]. Recently, computed 
ered as cardiac tumours but are not really true neo-
plasms (hamartoma and heterotopia). Approximately 
75% of cardiac tumours are benign, but they may have 
disabling or even lethal complications. Types of tumour 
are very different in adults and children, with a large 
majority of benign tumours being myxomas, lipoma-
tous tumours, or papillary fibroelastomas, whereas the 
same incidence of tumours in young patients aged 
<16 years is rhabdomyomas, teratomas, and fibromas. 
The four most common malignant primary cardiac 
tumours in adults are: angiosarcoma, rhabdomyosar-
coma, mesothelioma, and fibrosarcoma. Secondary 
cardiac tumours include metastases from extracardiac 
tumours disseminated via the blood or lymphatic sys-
tem. Carcinomas and melanoma are the main source of 
cardiac metastases, followed by secondary haemato-
logic malignancies (malignant lymphoma, multiple 
myeloma, and leukaemia) [5].
Due to the low incidence and the diversity in clini-
cal presentation, the diagnosis of primary cardiac tu-
mours may be missed or delayed. This may in part ex-
plain the morbidity and mortality associated with be-
nign cardiac tumours. Systemic or pulmonary 
thromboembolism is one of the most common factors, 
occurring in about 60% of cardiac tumours. Cerebral 
embolism is common in left-sided tumours, and tran-
sient ischaemic attacks or strokes are not unusual first 
symptoms. In addition, left-sided intracavitary tu-
mours may obstruct the mitral or aortic valve, whereas 
right-sided tumours are prone to obstruct the tricuspid 
or the pulmonary valve, thereby causing right cardiac 
failure and symptoms of obstructed right heart inflow, 
such as hepatomegaly, ascites and peripheral oedema. 
Intramyocardial tumours may cause arrhythmias and 
cardiac failure, while sudden death may be explained 
by the following mechanisms: arrhythmias, coronary 
obstruction or embolisation, tamponade cause by bleed-
ing or effusion, and valvular obstruction. 
Some tumours may cause unspecific general symp-
toms such as fever and fatigue as well as arthralgias 
and anaemia due to the release of tumour products 
such as interleukin-6, tumour necrosis factor or other 
neuroendocrine factors from the neoplastic tissue. 
Clinical examination is otherwise non-specific, how-
ever cardiac signs in patients who otherwise have no 
previous cardiac problems in association with general 
symptoms and embolic events should initiate cardiac 
investigation. Echocardiography is most often the first 
examination [6]. Magnetic resonance imaging gener-
ally allows a complete tumour diagnosis and planning 
of the operative procedure [7]. Surgery is indicated in 
the large majority of benign tumours and should be 
performed as soon as the diagnosis has been secured in 
order to avoid additional complications. 
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children [16]. Surgical excision is indicated in every pa-
tient. The classical approach is performed through the 
left atrium (incision in the interatrial groove) for in-
spection of the attachment to the atrial wall or the 
atrial septum [17]. Then the right atrium is opened and 
excision can be performed under sight. While a major-
ity of cardiac myxomas are definitively cured after sur-
gical resection, a small proportion may exhibit a more 
malignant evolution, characterised by local invasion or 
metastatic growth of tumour emboli [18]. Myxoma may 
have a familial occurrence in about 5% of the patients. 
In this case, they are less common in the left atrium 
(only in up to 60%), and are more often multiple (in up 
to 30%). Overall hospital mortality after removal of 
atrial myxomas should be less than 2–3%. Virtually, all 
deaths occur in older age patients with severe comor-
bidities. Supraventricular arrhythmias are quite fre-
quent after removal of atrial tumours. Recurrence is 
very rare and may be caused by incomplete excision or 
growth from a new focus [19].  
case report 1: benign myxoma
A 55-year-old woman without significant previous dis-
ease presented to the general practitioner with a tem-
perature of 37.5 °C, recurrent cough, progressive exer-
tional dyspnoea and impaired functional capacity 
(NYHA class II). A new diastolic heart murmur was 
noted. Because symptoms were associated with an in-
creased white cell count and elevated C-reactive pro-
tein levels, a possible diagnosis of infective endocardi-
tis was considered. The patient underwent transtho-
racic echocardiography. A mobile solid left atrial mass 
was found, which seemed to be attached to the anterior 
mitral cusp. Surgical exploration was indicated. After 
induction of anaesthesia, transoesophageal echocardi-
ography confirmed a large, hyperechogenic and pedun-
culated tumour with central echolucency. The tumour 
was attached to the base of the anterior mitral cusp be-
tween segments A1 and A2. During diastole, the mass 
tomography (CT) provides complementary information 
and, with the advent of electrocardiographic gating, 
has become a powerful tool in its own right for cardiac 
morphological assessment [11]. 
Benign cardiac tumours
Cardiac myxoma
Cardiac myxoma is the most frequent benign cardiac 
tumour. Myxomas account for more than 50% of all 
primary cardiac tumours in adults. Their incidence is 
highest among women aged 40 to 60 [12]. Usually a 
myxoma is a left atrial intracavitary mass (80 to 90%), 
originating from the septal surface of the left atrium, 
the roof and much more rarely close to the mitral valve 
anulus. More rarely, myxoma will grow in the right 
atrium or in the ventricles. In some rare cases, multi-
ple myxomas may appear, these are usually familial 
and develop at a younger age than a single myxoma. A 
myxoma is a sessile or pedunculated, polypoid tumour 
with a smooth but friable surface which may produce 
emboli and sometimes has areas of haemorrhage. Pa-
tients with a myxoma often present with one or more of 
the most classical symptoms: heart failure due to ob-
struction, stroke due to embolism (observed in 30 to 
45% of left-atrial myxoma), and constitutional symp-
toms (including fever, weight loss, or arthralgia) with 
inflammatory manifestations [12]. They may suffer 
from flow obstruction within a cardiac chamber (pul-
monary or systemic venous drainage) or obstruction of 
the atrio-ventricular valves. In addition to obstruction, 
impairment of mitral valve closure caused by the vicin-
ity of the tumour may lead to mitral valve regurgita-
tion. An organised thrombus represents the most im-
portant diagnostic entity to be differentiated from a 
myxoma. Sometimes, a thrombus can be adherent to a 
myxoma, making the differential diagnosis particu-
larly challenging [13]. In rare cases, mycoma can be at-
tached to the mitral valve [14, 15] or be observed in 
Figure 1
Large echolucent tumour with a broad attachment on the anterior mitral valve cusp and subvalvular mitral stenosis (A) with prolaps into the left 
ventricular outflow tract during diastole (B).
A B
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a more conventional myxoma. The tumour included a 
large amount of spindle and polygonal cells with poly-
morphic and hyperchromic nuclei and demonstrated a 
high mitotic rate. The postoperative course was une-
ventful and the patient was discharged from hospital 
one week after surgery. Two months later he suffered 
from generalised seizure. Computed tomography re-
vealed multiple frontal and occipital bilateral cerebral 
metastases. 
At this time, no recurrence was demonstrated 
within the heart. During the same hospitalisation, two 
soft tissue metastases – one located over the scapula 
and the other in the right gastrocnemius muscle – were 
resected. Histology of the resected metastases was 
consistent with that of the primary cardiac tumour. 
Complete staging of the patient demonstrated a fur-
ther metastasis located in the lower lobe of the right 
lung. After irradiation of the cerebral metastases with 
a total dose of 5000 Gy and five courses of chemother-
apy including adriamycine and ilosfamide the cerebral 
and pulmonary metastases disappeared completely 
and the patient still remained in complete remission 
six years after the initial resection of the atrial myx-
oma. However later the patient was lost to follow-up.
Papillary fibroelastoma
Papillary fibroelastoma is a rare cardiac tumour that 
was originally typically described at autopsy. Although 
cardiac papillary fibroelastoma is a benign tumour, it 
cannot be considered as harmless lesion, because sys-
temic embolic events are frequent and primarily in-
volve adults in their active period of life. Papillary 
fibroelastoma is the second most frequent cardiac tu-
mour and represents approximately 7% of cardiac 
tumours [12, 20]. Thanks to improved imaging modali-
ties, such tumours are relatively easy to detect and 
therefore are actively searched in patients with un-
clear cerebral or systemic embolic events but fre-
quently papillary fibroelastomas are discovered inci-
dentally. Echocardiography must therefore consider fi-
broelastoma in the differential diagnosis of every 
unclear embolic event, especially because surgical re-
section is most often curative. At coronary angiogra-
phy, fibroelastoma must be suspected in the presence 
of a mass near the coronary ostia or prolapsing into the 
left ventricular outflow tract [21]. Great care has to be 
taken because migration of further embolic materials 
may be facilitated by catheter manipulation. In partic-
ular, a papillary fibroelastoma must be considered 
when lysis or angioplasty do not restore a normal coro-
nary flow (see case report below). Once the diagnosis is 
considered, immediate termination of coronary angiog-
raphy is recommended. TTE can adequately screen for 
papillary fibroelastoma particularly when tumours are 
larger than 2 mm (sensitivity around 90%). However, 
if feasible, TEE is the preferred method because of its 
high resolution and improved imaging capabilities, 
prolapsed into the left ventricle, obstructing a major 
portion of left ventricular inflow (fig. 1), which in addi-
tion caused a moderate mitral stenosis (functional 
valve orifice area 1.05 cm
2
; mean transvalvular gradi-
ent 10 mm Hg). Surgical exploration was performed 
through a transseptal approach to the left atrium. The 
tumour was found to be attached to the anterior mitral 
cusp and the roof of the left atrium. Complete resection 
of the tumour left a defect in the anterior A1 part of the 
mitral cusp (fig. 2). This necessitated reconstruction of 
the cusp with a patch of xenopericardium, and of the 
mitral annulus, which was performed using a 26 mm 
Physio-II annuloplasty ring from Edwards Life- 
sciences. Post operative histological analysis revealed 
a mesenchymal tumour with myxoid matrix without 
atypical cells or necrosis [15].
case report 2: malignant myxoma 
A 31-year-old patient was admitted because of fever 
and exertional dyspnoea. He had suffered from a tran-
sient ischaemic attack with paresis of the left upper ex-
tremity prior to admission. Transthoracic echocardiog-
raphy revealed the presence of a left atrial mass that 
was considered to be the source of the cerebral embo-
lism. Surgery was performed through a combined left 
and right atrial approach [18]. A pedunculated tumour 
originating from the interatrial septum and prolapsing 
through the mitral valve into the left ventricle was re-
moved with a generous portion of the interatrial sep-
tum. Closure of the interatrial septum was performed 
with a pericardial patch. The macroscopic aspect of the 
tumour was polypoid, multilobulate and friable, thus 
typical for a left atrial myxoma. The histological prop-
erties of the tumour differed somewhat from those of 
Figure 2
Radically excised large (4–5 cm) left atrial myxoma with part of the 
anterior mitral cusp. (Reproduced from [15]: Erdös G, Reineke D, 
Basciani R, Carrel T, Eberle B. Left atrial myxoma attached to the 
anterior mitral leaflet with symptoms suggestive of infective  
endocarditis. Eur J Echocardiography. 2010;11:E8, by permission  
of Oxford University Press, Oxford, United Kingdom.)
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tic valve [12, 22]. In such cases, computed tomography 
or magnetic resonance imaging may be helpful. The ul-
timate diagnosis is usually made during operative re-
section and confirmed by histopathology.
case report 3: fibroelastoma
An 81-year-old woman presented with unstable angina 
and complained of chest pain during the last months. 
At coronary angiography, a thrombus was suspected 
in the proximal segment of the right coronary artery 
(fig. 3). Medical treatment using abciximab failed to re-
verse symptoms, as did angioplasty and stenting. Dur-
ing angiography, episodes of chest pain with inferior 
ST-segment elevation and hypotension occurred. Tran-
sthoracic echocardiography demonstrated the presence 
of a mass obstructing flow in the right coronary ostium 
(fig. 4). The patient was referred to surgery. Intraoper-
ative transoesophageal echocardiography confirmed 
the ostial obstruction of the RCA by a mobile, 12 to 
19 mm sized tumour located in the right coronary cusp 
of the aortic valve [23]. 
Surgical exploration was performed using stand-
ard cardiopulmonary bypass. A transverse incision 
was performed in the ascending aorta and the tumour, 
which was attached to the aortic cusp by a thin pedicle, 
was removed without damaging the aortic valve 
(fig. 5). A bypass graft to the distal right coronary ar-
tery using saphenous vein was performed. Weaning 
from cardiopulmonary bypass was uncomplicated and 
ischaemic ECG changes disappeared. The postopera-
tive course was uneventful, and the patient was dis-
charged home on the seventh postoperative day. Histo-
pathological examination confirmed the diagnosis of 
papillary fibroelastoma (fig. 6).
A review of the recent literature using medical 
search engines (PubMed, Medline) identified five case 
Figure 4
Echocardiography demonstrating the tumorous structure located in the right coronary cusp of the aortic valve. (Reproduced from: Frésard I, Stalder 
M, Gugger M, Goy JJ. Cardiac fibroelastoma causing angina. Eur H Journal. 2010;31:380, by permission of Oxford University Press, Oxford, United 
Kingdom.)
Figure 3
Coronary angiography (right coronary artery) showing a thrombus-like 
structure close to the right coronary ostium, involving the segment 1 
of the right coronary artery. (Reproduced from: Frésard I, Stalder M, 
Gugger M, Goy JJ. Cardiac fibroelastoma causing angina. Eur H 
Journal. 2010;31:380, by permission of Oxford University Press, 
Oxford, United Kingdom.)
particularly in regard to small sized tumours. In the 
majority of cases, the following features are present: 
small lesion of about 9–12 mm in diameter, homogene-
ous, mobile and pedunculated mass located on one of 
the aortic valve cusps. Echocardiography may fail to 
differentiate papillary fibroelastoma from other car-
diac masses such as tumours, thrombus, vegetation, 
valvular calcification, and Lambl’s excrescence. The 
latter are frond like growths that occur only along the 
closure lines of cardiac valves, predominantly the aor-
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are true neoplasms or myocardial hamartomas is still 
controversial, the latter is generally considered to be 
more likely. Rhabdomyoma frequently present soon af-
ter birth or in the first weeks of life with severe cardiac 
failure. 
Little is documented about the natural history of 
patients with cardiac rhabdomyomas. However, there 
are numerous reports which described spontaneous re-
gression in number and size of these tumours. This is 
the reason why surgery is not routinely indicated. Pa-
tients with life-threatening complications (haemody-
namic compromise due to valvular or ventricular out-
flow tract obstruction, recurrent hypoxic episodes or 
reports of coronary artery ostial occlusion caused by 
papillary fibroelastoma diagnosed during life [24]. 
Four patients presented with angina or myocardial in-
farction. One patient suffered primarily from embolic 
stroke due to a fibro-elastoma arising from the aortic 
wall, immediately next to the right coronary ostium. 
The RCA was involved in the majority of the cases ex-
cept in one, in which the tumour was localised close to 
the commissure between left and non coronary sinus 
with partial obstruction of the left coronary ostium 
causing intermittent angina and syncope. All patients 
were diagnosed by echocardiography and referred to 
surgery. A complete surgical removal with bypass 
grafting of the affected coronary artery system was 
performed in all patients. Replacement of the aortic 
valve was necessary only in one case because of the 
broad base of the fibroelastoma on the aortic cusp, pre-
cluding a valve-sparing technique. However, in the 
large majority of cases, papillary fibroelastoma of the 
aortic valve can usually be “shaved” from the affected 
valve cusp or excised and the corresponding cusp re-
constructed using a small piece of autologous pericar-
dium.
Rhabdomyoma
Rhabdomyoma is the most common benign tumour in 
children (up to 50% of tumours seen in childhood) with 
a majority of the cases diagnosed at prenatal ultra-
sound or in the first year of life. The tumour originates 
from cardiac myocytes. In a substantial proportion of 
cases, it is associated with tuberous sclerosis. Rhabdo-
myomas are located more often in the ventricle with 
both sides equally involved rather than in the atrial 
wall. They can be small or protrude largely into the 
cardiac cavities [12, 25, 26]. Whether rhabdomyomas 
Figure 5
Intraoperative view after transverse aortotomy showing the papillary fibroelastoma largely filling the right coronary cusp (left) and after complete 
resection and before shaving the base of the tumour. The leaflet was not damaged and valve function was normal after the procedure.  
(Reproduced from: Frésard I, Stalder M, Gugger M, Goy JJ. Cardiac fibroelastoma causing angina. Eur H Journal. 2010;31:380, by permission  
of Oxford University Press, Oxford, United Kingdom.)
Figure 6
Typical histological preparation (haematoxylin-eosin) of the papillary 
fibroelastoma. The central avascular fibrous core is a characteristic 
finding as is the peripheral myxomatous zone and the outer rim of 
hyperplastic endothelial cells. Stains specific for elastin helps usually to 
correctly identify the tumour. (Reproduced from: Frésard I, Stalder M, 
Gugger M, Goy JJ. Cardiac fibroelastoma causing angina. Eur H 
Journal. 2010;31:380, by permission of Oxford University Press, 
Oxford, United Kingdom.)
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refractory rhythm disturbances) are those who require 
surgical excision (fig. 7) [12]. Excision is limited to the 
area of the tumour and in some instances, only intra-
cavitary resection is performed as the remaining in-
tramyocardial portion may well regress spontaneously 
[26].
Degueldre and colleagues analysed the long-term 
cardiac and neurological outcome of 73 patients with 
cardiac rhabdomyoma in order to allow comprehensive 
prenatal counselling [27]. They analysed the number 
and location of the tumours to establish a potential as-
sociation with a diagnosis of tuberous sclerosis. The 
presence of multiple cardiac tumours suggested a high 
risk of being affected by tuberous sclerosis [27]. Car-
diac complications included arrhythmias, obstruction 
of the left ventricular outflow tract and secondary car-
diogenic shock. The importance of the diagnosis of tu-
berous sclerosis was exemplified by the neurodevelop-
mental complications, with 80% of the patients devel-
oping epilepsy, and 66% suffering from delayed mental 
and psychological development. The tumours usually 
regress after birth and cardiac-related problems are 
rare after the perinatal period.
Fibroma
Cardiac fibroma is another common benign tumour of 
the heart in children. They account for up to 10% of the 
cases. Fibromas are solitary tumours that grow pre-
dominantly in the anterior wall of the left ventricle or 
into the interventricular septum. As the name indi-
cated, the tumour is made of fibroblasts with a variable 
amount of collagen and elastic fibres. There is an asso-
ciation of cardiac fibroma with basal cell naevus syn-
drome (Gorlin) [28], which is characterised by multiple 
nevoid basal cell carcinoma of the skin. Patients with 
fibroma may become symptomatic with heart failure, 
ventricular arrhythmias and sudden death, although 
one third of the patients remain asymptomatic and tu-
mour is detected incidentally [12, 28]. In symptomatic 
cases, the tumour can be enucleated from the ventricu-
lar wall, when the tumour is very large, and complete 
resection seems impossible, partial resection may re-
sult in good palliation [25, 29, 30]. Exceptionally, car-
diac transplantation may be required when large and 
extensive tumour involvement precludes complete ex-
cision [12, 29].
case report 4: cardiac fibroma
A 14-months-old boy who suffered from loss of weight 
and increasing dyspnoea was referred for general ex-
amination. Cardiac auscultation revealed a systolic 
murmur and transthoracic echocardiography showed a 
40 × 25 mm tumour with the basis located at the ante-
rior wall of the right ventricle. The tumour practically 
filled the cavity of the right ventricle and extended up 
to 10 mm below the pulmonary valve. Elective surgery 
was performed and the tumour resected from trans-tri-
cuspidal and transventricular. The tumour was located 
in the ventricular wall and after enucleation (fig. 8), 
the endocardial layer was sutured to the epicardium to 
avoid intraparietal haematoma formation. A Gore-Tex 
patch was necessary to close the defect left in the ante-
rior wall of the right ventricle. The postoperative fol-
low-up was uncomplicated, the histology was typical 
for a cardiac fibroma. Follow-up echocardiography af-
ter three and twelve months showed normal intracar-
diac findings. Three years after surgery the child is do-
ing well without tumour recurrence [31].
Other rare cardiac tumours  
and tumour-like conditions
Primary cardiac haemangioma is an infrequent benign 
neoplasm which accounts for about 2% of all resected 
primary cardiac tumours [12, 32, 33]. The tumour is 
usually sporadic and may occur in patients of all age 
categories [34]. Haemangioma may cause pericardial 
effusion, congestive heart failure or arrhythmias. 
Rarely it affects the valve cusps. 
Lipoma is very rate but may occur anywhere in the 
heart with a predilection for the pericardium and the 
interatrial septum [12]. This type of tumour remains 
usually asymptomatic and is found incidentally by rou-
tine echocardiography, most frequently in younger pa-
tients. Lipomatous hypertrophy of the interatrial sep-
tum may be considered as a subform of lipoma. It is 
weakly associated with obesity and usually affects 
older individuals [35]. 
The calcified amorphous tumour of the heart most 
frequently represents a partially calcified intracavi-
tary mural thrombus [12], located most frequently in 
the ventricular cavities and more rarely in the atria or 
on the valves. There is an association of this finding 
with patients suffering from chronic renal failure, 
Figure 7
Excision of a large rhabdomyoma from the left ventricle in a neonate 
because of significant left ventricular outflow tract obstruction. 
Ventriculotomy at the level of the apex, tumour enucleation and 
closure of the LV with running suture using autologous pericardial strip 
for reinforcement. Note the close vicinity of the LAD.
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which may explain the severe calcification of the 
thrombus [36, 37]. Patients with a calcified thrombus 
may present with peripheral embolisation or other dis-
astrous arterial occlusion [38]. 
Mural thrombus in the heart can mimic cardiac tu-
mour. Intracardiac thrombus may be located in the 
ventricular or atrial cavities. When left-sided, they are 
a common cause of stroke or peripheral arterial embo-
lism. Thrombus of the right-heart side are detected in 
patients with pulmonary embolism [39]. In most cases, 
Figure 8
Echocardiography showing a large tumour into the right ventricle (*) with the attachment (arrow) at the anterior wall of the ventricle (A). Cardiac 
MRI confirmed the location of the tumour and showed that the tumour was largely floating in the right ventricle without any adhesions to the 
ventricular wall or the tricuspid valve. The tumour extended up to the right ventricular outflow tract (B). Intraoperative view after opening the 
anterior wall of the right ventricle (C). The endocardium and the epicardium were readapted after enucleation of the tumour. * shows the small 
transmural defect left at the site of the origin of the tumour to achieve complete resection (D). Reproduced with permission from Swiss Medical 
Forum. 2009;14:286–7.)
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the diagnosis of a cardiac thrombus is incidental and 
the majority of patients are asymptomatic [12]. The 
most frequent aetiology of cardiac thrombi are myocar-
dial infarction and dilated cardiomyopathy (left ventri-
cle), mitral valve disease and chronic atrial fibrillation 
(left atrium), whereas chronic abuse of anabolic ster-
oids or cocaine (fig. 9) and systemic diseases (chronic 
rheumatic diseases, coagulation disorders) may cause 
intracardiac thrombus in any of the cardiac chambers 
[40, 41]. 
Malignant cardiac tumours 
Malignant primary tumours consist of primary cardiac 
sarcomas, the most common type of cardiac tumour af-
ter myxoma [42]. Angiosarcoma represent approxi-
mately 35% of the malignant cardiac sarcoma. They oc-
cur in younger adults, usually originate from the atrial 
wall and may extend into the afferent veins (pulmo-
nary veins when located in the left atrium, superior or 
inferior vena cava when located in the right atrium) as 
well as into the corresponding atrio-ventricular valve. 
In rare instances, angiosarcoma may develop within 
the wall of the pulmonary artery or the vena cava, close 
to the heart [42, 43]. Rhabdomyosarcoma account for 
about 5% of cardiac sarcoma and derived from the stri-
ated muscle. Usually, rhabdomyosarcoma are large 
and grow into the myocardium but may also protrude 
into a ventricular cavity [42, 44]. Complete excision is 
rarely possible. Some patients are explored because the 
diagnosis is not clear before surgery, in others, surgical 
exploration allows tumour debulking. In these cases, 
adjuvant chemotherapy or radiotherapy may prolong 
life.
A retrospective study of primary cardiac tumours 
by Meng and colleagues showed that in histopathologi-
cal differentiation about 80% of primary cardiac tu-
mours were benign [45]. Among 31 cases with malig-
nant tumours unclassified sarcoma (23%), angiosar-
coma (19%) and rhabdomyosarcoma (19%) were the 
most frequent histological types of primary cardiac ma-
lignancies. Both, in myxomatous benign tumours and 
in primary malignant cardiac tumours the most com-
mon site of origin was the atrium. However, involve-
ment of the pericardium was significantly higher with 
malignant tumours (26% vs 0%, p <0.05) [4]. CT-scan 
and MRI is especially helpful in tissue characterisation 
and in defining the extent to which the cardiac tumour 
infiltrates surrounding structures [46]. FDG-PET is 
helpful in order to determine the dignity and existence 
of peripheral metastases before undergoing surgery 
[47]. Llombart-Cussac analysed 15 patients with pri-
mary cardiac sarcoma who underwent primary surgery 
and received a doxorubicin regimen within six weeks of 
surgery and adjuvant chemotherapy [48]. Twelve of the 
15 patients died after a median overall survival of 
12 months. The 2-year survival rate was 26%, but sur-
vival was significantly longer for patients following 
radical resection (22 vs 7 months).
Angiosarcoma
case report 5: Poorly differentiated angiosarcoma
A 49-year-old man presented with chest pain and 
shortness of breath. Laboratory showed elevation of 
D-dimers, but infection parameters were normal. CT 
scan of the chest excluded pulmonary embolism, but re-
vealed an infiltration of the right basal pulmonary lobe 
and pleural effusion. A mediastinal mass, located close 
to the right atrium, was detected and confirmed by 
transthoracic echocardiography. Pneumonia was 
treated with amoxicillin/clavulanic acid and clarithro-
mycin. Symptoms ameliorated significantly but soon 
after the patient experienced another episode of chest 
pain. Chest X-ray and CT-scan, again showed a density 
in the right basal pulmonary lobe, a significant right 
pleural effusion and prominent mediastinal lymph 
nodes. Contrast enhanced cardiac magnetic resonance 
Figure 9
Large tumour thrombus in a 28 years old male patient – most probably following chronic drug abuse, extending from the apex of the left ventricle 
into the left ventricular outflow tract (A) and obstructing the aortic valve during systole (B). 
A B
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imaging showed a retrocardial mediastinal mass of 
7.4 × 4 cm with compression of the right atrium and 
ventricle. Coronary angiography documented a strong 
vascularisation of the tumour originating from the 
right coronary artery. The FDG 18 uptake in positron 
emission tomography was increased in the mediasti-
num and in the region of the presumptive tumour with-
out evidence of distant metastases. The interdiscipli-
nary tumour board found surgery to be indicated. The 
tumour was resected, including the lateral wall of the 
right atrium, the adjacent pericardium and the vis-
ceral pleura. The free wall of the right atrium was re-
constructed using a xenopericardial patch. Pathologi-
cal examination revealed a spindle cell neoplasia with 
solid and papillary growth, including immature blood 
vessels lined by tumour cells and disseminated necro-
sis. Immunohistochemical staining was positive for vi-
mentin, CD31, CD34 and sporadic for factor VIII, indi-
cating that the tumour cells were derived from the en-
dothelium. These findings allowed the diagnosis of a 
poorly differentiated angiosarcoma. The patient re-
ceived chemotherapy with farmorubicin and haloxan, 
started two weeks after surgery.
Early diagnosis and radical excision are essential to 
long-term survival for primary cardiac sarcoma and can 
lead to long term survival, although this is rarely ac-
complished and overall results are very disappointing. 
Orthotopic cardiac transplantation is a controver-
sial treatment for primary cardiac sarcoma, but has 
been associated with prolonged survival in selected 
cases [49–51]. Cardiac transplantation for unresecta-
ble tumours has been described, although its use is lim-
ited by possible explosive recurrence postoperatively 
probably related to immunosuppressive therapy. In 
fact, the best option for very carefully selected patients 
theoretically remains orthotopic cardiac transplanta-
tion. It must integrate the resulting immunosuppres-
sive therapy as a prognostic factor of local relapse and 
distant metastases. In contrast, local extension, such 
as pericardial location may not exclude the possibility 
of transplantation. Although long term survivors are 
known to be extremely rare, the limited experience re-
ported by some authors in the literature confirms that 
heart transplantation, including in some cases a local 
pericardial and pleural resection, may be consistent 
with long term survival without relapse [49]. Despite 
the usual admittedly dismal prognosis related to the 
development of local or distant recurrence, cardiac 
transplantation can be mainly proposed for selected 
patients with no vascular cardiac sarcoma and no obvi-
ous distant metastases. Local and limited extracardiac 
extension (e.g.,pericardium) may not be considered as 
definitive contraindications but require additional sur-
gical resection.
Intracardiac extension of infradiaphragmatic 
malignant tumours
Infradiaphragmatic tumours extending through the 
inferior vena cava into the right atrium or the right 
ventricle do not usually lead to specific cardiac symp-
toms and are found by echocardiography or computed 
tomography during staging of the primary abdominal 
tumour. The most frequent tumours are the Wilms tu-
mours in children, hypernephroma, hepatocarcinoma 
and uterine leiomyosarcoma in adults [52, 53]. Natural 
history is not known but presumably right atrial exten-
sion worsens the prognosis associated with the pri-
mary tumour. In the last 15 years, we operated on 
12 adult patients presenting with renal cell carcinoma 
extending into the inferior vena cava and through the 
tricuspid valve into the right ventricle. Successful total 
removal was performed through a midline laparotomy 
and median sternotomy or through thoraco-phrenico-
laparatomy with the aid of normothermic cardiopulmo-
nary bypass (fig. 10). An aggressive therapeutic ap-
proach requiring operations of escalating magnitude 
and multidisciplinary surgical treatment was some-
times controversially discussed but could help salvage 
patients who otherwise would not have been consid-
ered for operation [52]. During the same time period, 
seven children were operated upon for a Wilms tumour 
with extension into the inferior vena cava and the right 
atrium. They underwent a similar procedure, with car-
diopulmonary bypass in three cases and with a veno-
atrial shunt being used during tumour extraction and 
reconstruction of the subhepatic inferior vena cava in 
two cases.
No perioperative mortality was observed in these 
patients, independently of the magnitude of these 
operations; mid-term survival – five years – was very 
satisfying with a tumour recurrence in 20% of the pa-
tients.
Nesbitt and co-authors analysed their experience 
with 37 patients suffering from renal cell carcinoma 
and inferior vena cava tumour thrombus who under-
went surgical resection between 1989 and 1996 [54]. 
The 27 men and 10 women had a median age of 57 
years. Distant metastases were present in 12 patients. 
Tumour thrombi extended to the infrahepatic inferior 
vena cava (n = 16), the intrahepatic inferior vena cava 
(n = 16), the suprahepatic inferior vena cava (n = 3), 
and into the right atrium (n = 2). All tumours were re-
sected by inferior vena cava isolation and, when neces-
sary, extended hepatic mobilisation, with primary or 
patch closure of the vena cavotomy. Cardiopulmonary 
bypass was necessary in only two patients with in-
traatrial thrombus. Complications occurred in 11 pa-
tients, and one patient died two days postoperatively of 
a myocardial infarction (mortality, 2.7%). Overall 2- 
and 5-year survival rates were 61.7% and 33.6%, re-
spectively. For patients without lymph node or distant 
metastases (stage IIIa), 2- and 5-year survival rates 
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were 74% and 45%, respectively. The presence of dis-
tant metastatic disease (stage IV) at the time of opera-
tion did not have a significant adverse effect on sur-
vival, as reflected by 2- and 5-year survival rates of 
62.5% and 31.3%, respectively. Lymph node metasta-
ses (stage IIIc) adversely affected survival as there 
were no long-term survivors. The authors concluded 
that resection of an intracaval tumour thrombus aris-
ing from renal cell carcinoma can be performed safely 
and results in prolonged survival even in the presence 
of metastatic disease. In their experience, extracorpor-
eal circulatory support was required only when the tu-
mour thrombus extended into the heart.
Endometrial stromal sarcoma (ESS) represents 
0.2% of all uterine malignancies. Based on the mitotic 
activity, a distinction is made between low and high-
grade ESS. Although the overall five-year survival rate 
for low grade ESS exceeds 80%, about 50% of the pa-
tients show tumour recurrence, mostly after a long la-
tency period. Tumour invasion of the great vessels is 
extremely rare but may occur and invade the inferior 
vena cava up to the right cardiac cavities. 
A review of the literature identified 19 patients, in-
cluding our own observation (see below), with advanced 
low grade ESS with invasion of the great vessels and a 
tumour thrombus in the inferior vena cava [55]. All pa-
tients presented with an abdominal tumour and a 
thrombus protruding into the inferior vena cava. The 
tumour thrombus extended into the right heart cavi-
ties in nine patients reaching the right atrium in four, 
the right ventricle through the tricuspid valve in three 
and the pulmonary artery in two patients. Five pa-
tients had advanced primary tumour and 14 suffered 
from advanced recurrent tumour. Seven patients pre-
sented with synchronous metastatic disease and six 
patients with a pelvic tumour infiltrating the bladder, 
the rectosigmoid colon or the infrarenal aorta. Median 
age at surgery was 47, ranging from 25 to 65 years). 
Tumour thrombectomy was performed by cavatomy or 
by right atriotomy under normothermic, beating heart 
cardiopulmonary bypass. There was no peri-operative 
mortality and a very low morbidity. Radical tumour re-
sections were achieved in ten patients. The follow-up 
for these ten patients was median 2 years, ranging up 
to 4.5 years. Nine patients showed absence of, whereas 
one patient suffered, an asymptomatic local recur-
rence.
Most authors claimed that resection of an inferior 
Figure 10
MRI of a patient with a renal carcinoma extending with a tumour thrombus into the inferior vena cava and through the tricuspid valve up  
to the right ventricle (A). Right atriotomy and excision of the tumour thrombus (B). Pathological specimen following radical excision (C).
A
C
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vena cava tumour thrombus, even with extension into 
the right heart cavities, can be performed safely. Ex-
tensive radical surgery is therefore justified in the 
treatment of advanced tumour manifestations of a low 
grade ESS, potentially improving recurrence free sur-
vival.
case report 6: endometrial stromal sarcoma  
with extension into the right heart
A 47-year-old female patient suffered from a low grade 
endometrial stromal sarcoma (ESS), a rare angioinva-
sive tumour with a high recurrence rate. She com-
plained of fatigue, shortness of breath and abdominal 
pain in September 2003. The past history included ex-
cision of a malignant melanoma on the left leg in 1974, 
and abdominal hysterectomy because of a myomatous 
uterus with leiomyoma in 1993. CT-scan demonstrated 
a retroperitoneal mass and biopsy revealed a low grade 
ESS. Preoperative MRI demonstrated a large retroper-
itoneal tumour with infiltration of the infrarenal aorta 
and the inferior vena cava. Moreover, there was a large 
tumour thrombus within the inferior vena cava which 
extended into the right atrium. Because of the intra-
cardiac tumour thrombus, the patient was judged to be 
at a high risk for acute heart failure and tumour embo-
lisation into the lungs. At the multidisciplinary tumour 
board, extensive surgical resection was recommended 
to achieve the most complete tumour clearance. Ap-
proach was performed through a median sterno-lapa-
rotomy. The tumour was mobilised, then cardiopulmo-
nary bypass was instituted following ascending aortic, 
superior vena cava and right external iliac vein cannu-
lation. En-bloc resection of the retroperitoneal tumour 
was performed with resection of the infrarenal aorta 
and of the anterior wall of the inferior vena cava. The 
infrarenal aorta was reconstructed using a straight 
graft. The infradiaphragmatic vena cava and the right 
atrium were opened. Complete extraction of the intra-
cardiac tumour thrombus was possible, since there 
were no adhesions to the wall of the vena cava or the 
right atrium. Reconstruction of the inferior vena cava 
was performed using xenopericardium. Applicators for 
postoperative brachytherapy were implanted in the 
iliac region and between the aortal graft and the recon-
structed inferior vena cava. The postoperative course 
was uneventful.
Follow-up examinations were carried out every six 
months. CT scans of the thorax, abdomen and pelvis 
showed no signs of tumour recurrence but seven years 
after the operation, she developed a recurrence at the 
level of the hepatic vein drainage into the inferior vena 
cava. Apart from occasional and unspecific abdominal 
discomfort, the patient reports very good health with a 
complete return to normal activities [55]. Radical re-
section was performed very recently again using cardi-
opulmonary bypass to control the retrohepatic vena 
cava.
Metastatic heart disease
Secondary malignant cardiac tumours are found at au-
topsy in 10–15% of patients with metastatic cancer dis-
ease. Cardiac metastases are among the least known 
and highly debated issues in oncology, and few system-
atic studies are devoted to this topic. The heart can be 
affected by any malignant neoplasm able to spread to 
distant sites. In general, cardiac metastases are con-
sidered to be rare. However, when sought for, the clini-
cal incidence seems to be not as low as expected, rang-
ing from 2.3% and 18.3%. Although no malignant 
tumours are known that diffuse preferentially to the 
heart, some do involve the heart more often than oth-
ers, for instance, breast and lung cancer, melanoma, 
plasmocytoma and mediastinal primary tumours [56–
58]) (fig. 11). Tumourous involvement of the pericar-
dium is quite common and causes pericardial effusion, 
carrying the risk of tamponade.
Secondary cardiac involvement may be overlooked 
in the constellation of symptoms associated with me-
tastasis but it usually occurs at the terminal phase of a 
prolonged disease course, especially in the setting of 
widespread metastatic disease [59, 60]. 
In the specific instance where secondary cardiac 
involvement leads to the initial diagnosis of malig-
nancy, or is the first evidence of small volume meta-
static recurrence, aggressive surgical management 
may result in long term survival, provided that all 
gross tumour can be excised [59, 60]. Surgery would be 
expected to be most beneficial in patients whose pri-
mary tumour is under control and who have a signifi-
cant disease-free interval between control of the pri-
mary tumour and detection of the cardiac metastasis. 
In patients with recurrent pericardial effusion, simple 
or multiple punctions may be helpful, other patients 
Figure 11
Large plasmocytoma metastasis located at the level of the atrio-ventric-
ular groove and invading the right atrium with consecutive severe 
tricuspid stenosis. Tumour debulking only was performed with 
reconstruction of the atrial wall using xenopericardium. 
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are best treated by creation of pleuro-pericardial win-
dow through a thoracoscopy or pericardio-abdominal 
window through a small subxyphoidal approach.
It is not known whether adjuvant chemotherapy is 
beneficial in patients who have undergone curative 
surgery. Chemotherapy is the treatment of choice for 
cardiac neoplasms that have metastasised. The role of 
radiation in the treatment of cardiac tumours is not 
well defined [60]. Although radiation is the therapy of 
choice for malignant lymphomas, when combined with 
chemotherapy, it significantly increases the risk for 
myocardial and pericardial damage. 
Carcinoid heart disease
Malignant carcinoid syndrome is a group of symptoms 
associated with carcinoid tumours from the gastroin-
testinal system arising from cells which produce large 
amounts of serotonin. The syndrome is characterised 
by flushes, diarrhoea and bronchospasms. Carcinoid 
heart disease is a manifestation of malignant carcinoid 
syndrome in which a unique form of fibrosis affects the 
endocardium, predominantly of the right heart cavi-
ties. Most patients have pathologic lesions limited to 
the tricuspid and pulmonary valves. The fibrous depos-
its lead to constriction of the valve annulus and adher-
ence of the valve cusps to the right ventricular endocar-
dium (tricuspid valve) or the pulmonary artery wall 
(pulmonary valve). A large majority of patients with 
carcinoid heart valve lesions suffer from hepatic me-
tastases from the primary intestinal tumour. In echo-
cardiography, the valve cusps are shortened and thick-
ened and most patients show moderate to severe tri-
cuspid regurgitation [61]. 
Progress in the medical and surgical management 
of patients with carcinoid disease has resulted in im-
proved palliation and survival. Limited medical treat-
ment options are available for patients with sympto-
matic carcinoid heart disease. Patients with severe car-
cinoid heart disease are currently referred for cardiac 
operation when they develop cardiac symptoms, ven-
tricular dysfunction, or (rarely) in anticipation of 
hepatic surgery. Surgical outcome depends on patient 
age and functional class at the time of cardiac surgery. 
Despite metastatic disease that limits longevity, car-
diac surgical survivors usually demonstrate dramatic 
improvement in functional capacity. Cardiac surgery 
should be considered early for patients with sympto-
matic carcinoid heart disease and controlled carcinoid 
symptoms. An experienced medical, surgical and an-
aesthetic team approach to the patient with carcinoid 
heart disease is critical in order to provide state of the 
art management.
Perioperative management of patients with carci-
noid heart disease may challenge the anaesthetist be-
cause of two problems: carcinoid crisis and low cardiac 
output secondary to right ventricular failure. Carci-
noid crises may be precipitated by the administration 
of catecholamines and histamine-releasing drugs. The 
group from Mt. Sinai Hospital, NY analysed a series of 
11 patients with severe symptomatic carcinoid heart 
disease who underwent multivalve surgery (right-
sided valves, n = 8; right- and left-sided valves, n = 3) 
between 2001 and 2007 [62]. All patients received 
octreotide intraoperatively [650 (300–1050) µg] to 
prevent carcinoid symptoms and vasoplegia. Those pa-
tients on a higher preoperative octreotide regime re-
quired additional intraoperative octreotide (range) 
dose 300–850 vs 650–1050 µg. Similarly, the use of 
larger doses of aprotinin (>5 KIU) was associated with 
higher requirements for octreotide. Catecholamines 
were generally required in those patients who pre-
sented with a worse New York Heart Association func-
tional class. Overall mortality was 18% (n = 2) and only 
one episode of mild intraoperative carcinoid crisis was 
observed. The authors concluded that carcinoid crisis 
and right ventricular failure still remain the primary 
challenges for the anaesthetist while managing pa-
tients with carcinoid heart disease. The study supports 
the administration of catecholamines to wean patients 
off cardiopulmonary bypass, particularly in the pres-
ence of myocardial dysfunction. Those patients on 
higher octreotide dosages required close intraoperative 
glucose monitoring. Earlier patient referral and more 
comprehensive perioperative management may im-
prove the results in these critically ill patients.
Tricuspid and pulmonary valve replacement rather 
than repair may provide some palliation, but perioper-
ative mortality is described as high as 20% [63, 64]. In 
a series published in 2011, Dreyfus and colleagues 
analysed 22 patients with carcinoid heart disease 
undergoing cardiac valve surgery [65]. Three patients 
underwent tricuspid valve replacement alone, 15 pa-
tients underwent tricuspid and pulmonary valve re-
placement, two patients underwent tricuspid, pulmo-
nary and mitral valve replacement and two patients 
underwent quadruple valve replacement. Overall 
30-day-mortality was 18%. Cause of death was right 
ventricular dysfunction (two), refractory carcinoid cri-
sis (one) and pneumonia (one). Four patients required 
a permanent pacemaker for complete heart block. Of 
those who survived initial surgery, median follow-up 
was 26 months (interquartile range 8–42); one- and 
two-year survival rates were 56% and 44%, respec-
tively. The authors found no significant difference in 
survival between those patients in the New York Heart 
Association (NYHA) class I/II, mild/moderate right 
ventricular dilatation or N-terminal brain natriuretic 
peptide (NT-proBNP) <1245 pgml (-1) compared with 
those in NYHA class III/IV, severe right ventricular 
enlargement or NT-proBNP >1245 pgml (-1), respec-
tively. Long term causes of death were related to 
advanced metastatic carcinoid tumour. No patient re-
quired re-operation for bioprosthetic degeneration. 
Dreyfus and colleagues concluded that valve surgery 
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for carcinoid heart disease is of higher risk compared 
with most other forms of valvular surgery. In patients 
who survived the operation significant improvement in 
functional class occurred. Most long term complica-
tions were related to the tumour itself rather than car-
diac complications.
Own experience
In table 1, we summarised our experience with all 
types of tumours treated in the time period between 
1996 and 2010. We have operated on 95 patients (mean 
age 58 years, ranging from 44 to 82 years) with a be-
nign cardiac myxoma. Distribution male: female was 
1:1.4. The 30-day mortality rate was 1/95 (1.05%); one 
patient did not recover from a preoperative stroke and 
died from neurologic complications at postoperative 
day 10. The estimated survival (Kaplan-Meier) at 10 
years was 86%. There were no recurrence so far.
In the same time period, we operated on 12 adult 
patients and seven children presenting with renal cell 
carcinoma (resp. Wilms tumour) extending either into 
the inferior vena cava (n = 4) or more cranially into the 
right atrium (n = 12) and in some instances through 
the tricuspid valve into the right ventricle (n = 3). Suc-
cessful total removal was performed through midline 
laparotomy and median sternotomy or through thoraco-
phrenico-laparatomy with the aid of normothermic 
cardiopulmonary bypass. There was no perioperative 
mortality in these cases. Recurrence occurred within a 
mean interval of 11 months in three patients.
The experience with malignant and/or metastatic 
tumour has been much more disappointing. Not in-
cluded in this short summary are the pericardial drain-
age and/or the creation of pericardial window (into the 
pleura or the abdominal cavity) to treat recurrent ma-
lignant pericardial effusion.
Conclusion
Primary cardiac tumours are rare, with an autopsy in-
cidence ranging from 0.001% to 0.03% according to 
different series. 75% of these tumours are benign and 
nearly 50% of the benign tumours are left or right 
atrial myxomas. Primary cardiac tumours present 
with one or more of the symptoms of the classic triad of 
cardiac symptoms and signs resulting from intracar-
diac obstruction, signs of systemic embolisation, and 
Table 1 
Experience with tumour surgery of the heart (Berne, 1996–2010).
Benign cardiac tumours n  
Myxoma 95  
Papillary fibroelastoma 14  
Fibroma (children) 4  
Rhabdomyoma 1   
Malignant tumours n Deaths within 1 yr
Primary malignant cardiac  
tumours 
 
  
Sarcoma (not otherwise specified) 2 1
Angiosarcoma (SVC, IVC, PA) 6 1
Leiomyosarcoma 3 2
Infra-diaphragmatic tumours 
 
 
Wilms tumour 7 1
Renal cell carcinoma 12 –
Endometrial stromal cell sarcoma 1 –
Metastatic heart tumour 
 
 
 
 
 
 
 
 
 
 
 
 
Metastatic lung carcinoma: debulking RV 1 1
Metastatic thyroid carcinoma: debulking RA, RV 1 1
Non Hodgkin Lymphoma: debulking RV, Pericardium 1 1
Synovialom RV: resection + tricuspid valve replacement 1  
Plasmocytoma RV/RA: partial resection 1 1
Chorio-Carcinoma: resection pulmonary veins, LA 1 –
Melanoma RV: palliative resection (debulking) 1 1
Hamartoma LA: curative resection + MVR 1 –
Haemangiosarcoma RV/RA: palliative resection  –
Lymphangiosarcoma LV: palliative resection 1 1
Carcinoid heart disease (TVR + PVR)  9 1
SVC = superior vena cava; LV = left ventricle; VC = inferior vena cava; LA = left atrium; PA = pulmonary artery; MVR = mitral valve 
replacement; RV = right ventricle; TVR = tricuspid valve replacement; RA = right atrium; PVR = pulmonary valve replacement.
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systemic or constitutional symptoms. The majority of 
cardiac tumours are diagnosed using transthoracic 
and transoesophageal echocardiography, MRI, and CT 
scan. Whereas surgery is almost always indicated in 
patients with benign tumours, systemic chemotherapy 
is indicated in those who have widespread or unresect-
able malignant disease, and chemotherapy and radio-
therapy are usually combined in treatment of patients 
with primary cardiac lymphomas. Cardiac sarcomas 
represent the most frequent histology of primary ma-
lignant cardiac tumours, with angiosarcomas making 
up 33% of the cases. 
The prognosis after surgery is usually excellent in 
the case of benign tumours (with a perioperative mor-
tality below 1.5%) and with a minimal number or ab-
sence of recurrence. Unfortunately the prognosis is 
still limited in localised malignant diseases. Patients 
with sarcomas live for a mean of three months to one 
year, and those with lymphomas may reach a life ex-
pectancy up to five years if treated. Metastases to the 
heart are far more common than primary cardiac tu-
mours but they do not usually present to the cardiac 
surgeons because of the overall dismal prognosis.
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